Review Papers Claim by Claim

Figure 1 — Pregnancy outcomes after euploid embryo transfer (PGT-A cohort)

Data source: PGT-A cohort reported in the study: young (n=576) vs middle-aged (n=573); biochemical pregnancy, clinical pregnancy and live birth rates are significantly lower in the middle-aged group after excluding aneuploid embryos, implying an endometrial contribution to the fertility decline (see Methods for cohort selection and exclusion criteria).

Clinical cohort (Wang et al. 2025)

Figure 2 — Mechanistic summary (H3K27ac → PGR → endometrial receptivity)

This conceptual flow mirrors the authors' core experimental chain: (1) clinical association that endometrial aging reduces reproductive success; (2) CUT&Tag and IF showing stromal H3K27ac loss in aging; (3) PGR depletion (mRNA/protein and genome-wide binding loss) in aging stromal cells; (4) A485 (p300 inhibitor) reduces H3K27ac and lowers PGR in young stromal cells; (5) uterine A485 injections in mice reproduce aging-like transcriptional and receptivity defects including implantation failure. All assertions are directly supported by the main study data and analyses.

Molecular chain from H3K27ac loss to PGR loss (Wang et al. 2025)

Concise critical appraisal (visual first, then evidence)

• Strength — multi-level evidence: human cohort data, cell-type RNA-seq, CUT&Tag for H3K27ac and PGR, biochemical perturbation (A485), co-IP, and mouse validation form a coherent, cross-platform chain of evidence linking H3K27ac loss to PGR depletion and receptivity defects (Paper multi-modal evidence).
• Limit — causality and specificity: A485 is a global p300 inhibitor; loss of H3K27ac genome-wide can have pleiotropic effects beyond the PGR promoter. The study cannot yet show region-specific H3K27ac editing (e.g., locus-directed acetylation/deacetylation) to unambiguously ascribe phenotypes solely to PGR promoter/enhancer acetylation (authors acknowledge this limitation) (Limit: global H3K27ac inhibition).
• Limitation — cohort & generalizability: retrospective single-center PGT-A dataset controls for embryonic aneuploidy but remains demographically constrained; replication in independent, ethnically diverse cohorts would strengthen claims (Cohort characteristics and limitations).
• Species differences: mice are a credible validation model but decidualization differs between humans and mice (humans: cyclical decidualization; mice: post-implantation decidualization). Thus some mechanistic or temporal inferences may not fully translate (Species decidualization caveat).

Figure 3 — Summary quantitative directionality (qualitative fold-change visual)

Note: plotted values are illustrative summaries of reported directions/magnitudes across assays (RNA-seq log2 FC for PGR = approx. −1.99; protein reductions reported qualitatively and by densitometry; H3K27ac reductions were prominent in CUT&Tag/IF). Use the raw deposited datasets (HRA007501 / OMIX008964 / CRA022502) for exact numeric reanalysis; I provide a bioinformatics agent button below to run reproducible re-analyses.

Reported fold-changes and peak counts

Detailed synthesis, blindspots, and falsification criteria

What the paper establishes (evidence-weighted)

1. Clinical association: In a controlled PGT-A setting excluding embryonic aneuploidy, middle-aged patients had lower implantation/pregnancy/live-birth rates, supporting a uterus/endometrium contribution to age-related fertility decline (Clinical association data).
2. Epigenetic signature: Aging mid-secretory human endometrium (stromal cells) shows genome-wide H3K27ac depletion by CUT&Tag and IF; genes with H3K27ac loss are enriched in Wnt/BMP/ECM/cell-cycle pathways relevant to receptivity (H3K27ac CUT&Tag results).
3. PGR reduction & occupancy loss: PGR mRNA/protein are reduced in aging endometrium; PGR CUT&Tag shows broad loss of PGR binding in aging stromal cells, and genes losing both PGR and H3K27ac are enriched for receptivity pathways (Wnt, MAPK, ECM) (PGR expression and cistrome changes).
4. Functional perturbation: Pharmacologic inhibition of p300 with A485 in young human stromal cells reduces H3K27ac and lowers PGR; intra-uterine A485 injection in mice eliminates uterine H3K27ac, reduces Pgr and causes implantation failure mimicking aging features; RU486 (antiprogesterone) causes aging-like transcriptional changes without reducing H3K27ac, supporting H3K27ac→PGR directionality (A485 and RU486 perturbations in vitro/in vivo).

Key blindspots, alternative explanations, and how to falsify

• Global vs locus-specific effect: A485 blocks p300/CBP HAT activity globally; phenotypes may reflect cumulative loss of enhancer acetylation beyond PGR regulatory regions. Falsification test: locus-specific re-acetylation (e.g., dCas9–p300 to restore H3K27ac at PGR promoter/enhancer) in A485-treated or aged stromal cells should rescue PGR expression and decidualization if the mechanism is locus-specific. If rescue fails, H3K27ac loss acts more broadly or via metabolic/structural changes (Authors).
• Upstream cause of H3K27ac loss: The paper posits potential metabolic (acetyl‑CoA) decline as a driver but does not test it. Falsification test: measure acetyl‑CoA, ACLY/ACSS expression and flux in aging endometrium; restore acetyl‑CoA (metabolic supplementation or ACLY activation) to test whether H3K27ac and PGR recover. If acetyl‑CoA restoration rescues H3K27ac/PGR, an upstream metabolic mechanism is supported.
• Cellular heterogeneity and cell-type causality: stromal cells were the primary focus (H3K27ac loss pronounced there); epithelial cells showed different aging signatures (excess proliferation). Single-cell multi-omic tests (scRNA + scCUT&Tag / single-nucleus CUT&Tag) across large donors would define cell-type-specific causal chains and avoid bulk averaging confounders. The study's CIBERSORTx estimate of cell composition is helpful but cannot substitute single‑cell resolution (Cell-type analyses and limits).
• Population & external validity: cohort selection excluded major uterine disease but demographic/ethnic/assay variability and unknown environmental exposures may affect generalizability; independent cohorts and prospective studies are needed for translation into clinical biomarkers.

Confidence & what would overturn the paper's core claim

Confidence in the central mechanistic chain (H3K27ac loss → PGR depletion → impaired receptivity) is moderate-to-high given multi-modal convergent evidence, but it is not airtight because region-specific causality is unproven. Evidence that would overturn the conclusion: (a) locus-specific restoration of H3K27ac at PGR regulatory elements fails to restore PGR expression/function, or (b) independent cohorts show no reproducible H3K27ac/PGR correlation with age or no effect on implantation when H3K27ac is modulated, or (c) PGR levels remain stable when H3K27ac is lowered by orthogonal methods in multiple models.

Practical takeaways & next experiments (concise)

• Prioritize locus-specific epigenome editing (dCas9–p300 vs dCas9–KRAB/HDAC) at candidate PGR promoters/enhancers in primary human stromal cells to test direct causality.
• Measure acetyl‑CoA and metabolic enzyme activity (ACLY, ACSS2) in young vs aged endometrium; test metabolic supplementation rescue of H3K27ac and PGR.
• Replicate CUT&Tag and RNA-seq in independent, ethnically diverse clinical cohorts and perform single-cell multi-omic profiling for cell-type causal mapping.
• Explore temporal dynamics across the cycle (proliferative → secretory) to determine whether H3K27ac loss is progressive or phase-specific.

If you want, I can: (1) run the deposited CUT&Tag/RNA-seq datasets (HRA007501 / OMIX008964 / CRA022502) to reproduce key figures (peak calling, differential binding, peak–gene linking), or (2) generate locus plots for PGR/FOXO1/HOXA10 showing H3K27ac and PGR signals — click "Run AI Scientist Analysis" above to start.

All claims in this analysis reference the primary paper and its deposited datasets; see citations inline. I have emphasized experimental design strengths and limitations, potential confounders, and concrete falsification strategies.